For laboratory and research use only. Not for human consumption.
Comparison

Snap-8 vs Oligopeptide-1

Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research

Snap-8

Also: Acetyl Octapeptide-3, SNAP-8

Research

SNAP-8 (Acetyl Octapeptide-3) is a synthetic eight-amino-acid topical cosmetic peptide, an extended cousin of Argireline that adds two residues to the same SNAP-25 mimic sequence. It is marketed as a needle-free way to soften expression lines, especially on the forehead and around the eyes. It is a cosmetic ingredient, not an approved drug, and the human evidence behind it is thin and mostly comes from the manufacturer.

Skin & HairLimited Research
Oligopeptide-1

Also: sh-Oligopeptide-1, rh-Oligopeptide-1

Clinical Trials

sh-Oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (EGF), a 53-amino-acid protein your skin uses to tell cells to divide and repair. It shows up in 'EGF serums' aimed at wrinkles, texture and post-procedure recovery. It is a cosmetic ingredient in skincare, not an FDA-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled.

Skin & HairHuman Trials

Key Comparison Insights

  • Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
  • Oligopeptide-1 has stronger research evidence (Human Trials) compared to Snap-8 (Limited Research).

Detailed Comparison

AttributeSnap-8Oligopeptide-1
CategorySkin & HairSkin & Hair
FDA StatusNot FDA ApprovedNot FDA Approved
Clinical Status
Pre
I
II
III
IV
FDA
Pre
I
II
III
IV
FDA
Mechanism of ActionThe pitch is that SNAP-8 imitates the tip of SNAP-25, a protein nerves use to dock and release acetylcholine, the signal that tells facial muscles to contract. By competing for a spot in the SNARE complex that drives that release, the peptide is meant to dial down muscle firing and therefore the creasing those muscles cause, a gentler, reversible echo of how Botox works. The honest catch is that this is a proposed mechanism inferred from its sequence and from cell and test-tube work, not something confirmed to happen in living facial muscle after you rub on a cream. SNAP-8 is hydrophilic and fairly large, so getting enough of it down through the skin to reach muscle is the central unsolved problem.EGF binds the EGF receptor on keratinocytes and fibroblasts and switches on growth and repair signaling: cell division, migration, and production of matrix proteins. That is why it has been studied for wound healing, and why cosmetic brands use it to support skin renewal. Two practical problems: EGF is a fairly large protein, so getting it through intact skin is hard (which is why many studies pair it with microneedling or lasers), and it is fragile, so how much stays active in a jar at room temperature is a fair question. The same growth-promoting signal is also the source of the safety debate: EGF receptor signaling drives several cancers, so the concern is not that EGF causes cancer, but whether it could encourage abnormal cells that are already there.
Common Dosing
Limited community data available
See research protocols
Low parts-per-million concentration in a serum
Once or twice daily
AdministrationTopical (serums, creams)Topical (serums, ampoules, creams); sometimes combined with microneedling in clinic
Typical DurationOngoing use for maintained effectsStudies typically ran 4 to 12 weeks
Best Time to TakeEvening (topical)Evening skincare routine, or right after an in-clinic procedure
Possible Side Effects
May vary by individual
  • Generally very well-tolerated
  • Mild tingling (first applications)
  • Mild skin irritation (high concentrations)
  • No systemic toxicity
  • Mild redness, burning or itching (transient)
  • Irritation, especially when used after microneedling
  • Theoretical concern about stimulating existing abnormal or cancerous skin cells (unproven, but untested long term)
  • People with skin cancer history, many atypical moles, or psoriasis should ask a dermatologist first
Research SummaryThere is no robust independent clinical trial library for SNAP-8 specifically. Most of the impressive numbers you see, such as large percentage drops in wrinkle depth over four weeks, trace back to manufacturer literature rather than peer-reviewed, placebo-controlled studies. The science is best understood by looking at its parent peptide Argireline (acetyl hexapeptide-8), where the picture is genuinely mixed: the original 2002 Blanes-Mira study reported roughly 30 percent wrinkle-depth reduction with a 10 percent cream, but a later independent split-face human trial using VISIA imaging found no statistically significant difference between the peptide side and placebo. A 2025 review of acetyl hexapeptide-8 also flagged that skin-penetration data conflict sharply and that none of the in vivo studies actually confirmed muscle inhibition, the supposed mechanism. So for SNAP-8, treat the marketing claims with caution: plausible idea, real cosmetic-ingredient status, weak and largely company-sourced human proof.A 2021 systematic review in the Journal of Cutaneous and Aesthetic Surgery (Miller-Kobisher and colleagues) found 49 articles on rhEGF for skin, including 23 aesthetic studies. Most reported less wrinkling, better hydration and elasticity, and the strongest data were for pigmentation after lasers and melasma. But the authors admit many trials were uncontrolled or not randomized, samples were often 8 to 40 people, and they called for proper controlled trials. Adverse effects were mild and short-lived. The review did not address cancer risk at all, which is a real gap. Several of the better-known growth-factor trials tested multi-factor mixtures, not EGF alone. On safety: there is no human evidence that cosmetic EGF causes skin cancer, and in vitro tests of growth-factor cosmetics on melanoma cells were reassuring, but long-term studies in healthy skin do not exist. Sensible caution: people with a history of skin cancer, many atypical moles, or active psoriasis should talk to a dermatologist before using it. Bottom line: plausible and widely used, modest and mostly low-quality efficacy data, and an unresolved theoretical safety question.

Frequently Asked Questions: Snap-8 vs Oligopeptide-1

What is the difference between Snap-8 and Oligopeptide-1?

Snap-8 is a skin & hair peptide that snap-8 (acetyl octapeptide-3) is a synthetic eight-amino-acid topical cosmetic peptide, an extended cousin of argireline that adds two residues to the same snap-25 mimic sequence. it is marketed as a needle-free way to soften expression lines, especially on the forehead and around the eyes. it is a cosmetic ingredient, not an approved drug, and the human evidence behind it is thin and mostly comes from the manufacturer. Oligopeptide-1 is a skin & hair peptide that sh-oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (egf), a 53-amino-acid protein your skin uses to tell cells to divide and repair. it shows up in 'egf serums' aimed at wrinkles, texture and post-procedure recovery. it is a cosmetic ingredient in skincare, not an fda-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled. The main differences lie in their mechanisms of action and clinical applications.

Which is better, Snap-8 or Oligopeptide-1?

Neither is universally "better" - the choice depends on your specific goals. Snap-8 is typically used for skin & hair purposes, while Oligopeptide-1 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.

Can Snap-8 and Oligopeptide-1 be used together?

Some peptide protocols combine multiple compounds for synergistic effects. However, using Snap-8 and Oligopeptide-1 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.

Related Comparisons

View Full Peptide Profiles